Holen Sie sich die Stockscreener-App
7.16
6.07%
0.41
Handel nachbörslich:
7.20
0.04
+0.56%
Schlusskurs vom Vortag:
$6.75
Offen:
$6.97
24-Stunden-Volumen:
8.12M
Relative Volume:
1.55
Marktkapitalisierung:
$2.56B
Einnahmen:
$9.68M
Nettoeinkommen (Verlust:
$-250.64M
KGV:
-5.115
EPS:
-1.3998
Netto-Cashflow:
$-89.83M
1W Leistung:
+4.53%
1M Leistung:
+44.65%
6M Leistung:
+58.76%
1J Leistung:
+122.36%
1-Tages-Spanne:
$6.80
$7.21
1-Wochen-Bereich:
$6.08
$7.21
52-Wochen-Spanne:
$2.9421
$7.32
Precigen Inc Stock (PGEN) Company Profile
Firmenname
Precigen Inc
Sektor
Branche
Telefon
301-556-9900
Adresse
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
7.16 | 2.42B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
552.06 | 133.88B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
840.84 | 83.42B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
174.38 | 25.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
1,032.86 | 62.12B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
214.66 | 46.30B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-15 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-03-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-05-23 | Eingeleitet | JP Morgan | Neutral |
| 2022-11-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-25 | Eingeleitet | Stifel | Buy |
| 2021-02-22 | Eingeleitet | Wells Fargo | Overweight |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-05-08 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Precigen Inc Aktie (PGEN) Neueste Nachrichten
Precigen (PGEN) Stock: Ends Up by 6.30% at $7.17 in the Latest Session; Key Range: Support at $6.81 and Resistance at $7.53 Frame the Range under the Current SnapshotPut Spread Alert - Vinanet
Stock Traders Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat
Alpine Woods Capital Investors LLC Takes $1.31 Million Position in Precigen, Inc. $PGEN - MarketBeat
$Precigen (PGEN.US)$ DCA'd Up. Ready for the next leg higher - Moomoo
Precigen (PGEN) Price and Levels: Finishes 3.05% Higher at $6.75 in the Latest Session; $6.41 and $7.09 Define the Nearby Reference Levels at the CloseCounter Trend Trade - Vinanet
Precigen Inc. (PGEN) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Precigen (NASDAQ:PGEN) Stock Price Up 5.5%Time to Buy? - MarketBeat
Precigen Inc (PGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precigen (NASDAQ:PGEN) Trading Down 5.5%What's Next? - MarketBeat
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice - Yahoo Finance
Precigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo! Finance Canada
Can Precigen (PGEN) Justify Its Valuation On Earnings And PAPZIMEOS Launch? - Yahoo Finance
US High Growth Tech Stocks To Watch: 3 Top Picks - simplywall.st
Precigen (PGEN) Q2 2026 Earnings Call Transcript - AOL.com
Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage - webull.com
Precigen (PGEN) Insider Rutul Shah Sells 32,739 Shares - GuruFocus
Precigen jumps 266% on FDA approval but faces h... - Pluang
Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy" - MarketBeat
Precigen: Has To Grow Into Its Valuation - Seeking Alpha
Precigen (NASDAQ:PGEN) COO Sells $224,589.54 in Stock - MarketBeat
COO sale: Precigen (PGEN) insider trades 32,739 shares via plan - Stock Titan
Merck affiliates disclose 4.9% Precigen (NASDAQ: PGEN) ownership - Stock Titan
HC Wainwright Has Positive Outlook for Precigen Q3 Earnings - MarketBeat
Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Zacks Research - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Strong Growth Potential With An 80% Upside - DirectorsTalk Interviews
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement (PGEN) - Seeking Alpha
PRECIGEN, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $14 - webull.com
Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale - Stock Titan
HC Wainwright Predicts Precigen's Q4 Earnings (NASDAQ:PGEN) - MarketBeat
Results: Precigen, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Precigen (NASDAQ:PGEN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN - MarketBeat
Precigen, Inc. (PGEN) Interactive Stock Chart - Yahoo! Finance Canada
Germantown biopharma Precigen turns first quarterly profit after key drug scores FDA approval - The Business Journals
Precigen (NASDAQ:PGEN) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Precigen, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved - GuruFocus
Is Precigen Inc (PGEN) Overvalued After Q2 Earnings Beat? GF Sco - GuruFocus
Earnings call transcript: Precigen tops Q2 2026 forecasts as PAPZIMEOS sales surge - Investing.com
Precigen (NASDAQ:PGEN) Announces Earnings Results - MarketBeat
Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Precigen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Precigen (PGEN) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Precigen Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PGEN) Precigen, Inc. Reports Q2 Revenue $55.0M, vs. FactSet Est of $28.0M - marketscreener.com
PGEN: Profitability reached as PAPZIMEOS drives record revenue and broad US adoption - TradingView
PRECIGEN, INC. 2026: Revenue $54.98M, EPS $0.05— 10-Q Summary - TradingView
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth - Yahoo Finance
Precigen earnings set to test gene therapy growth trajectory By Investing.com - Investing.com Nigeria
Precigen earnings set to test gene therapy growth trajectory - Investing.com
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Finanzdaten der Precigen Inc-Aktie (PGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):